AstraZeneca Korea launched various activities to raise awareness of respiratory diseases in infants and young children on the occasion of ‘World Early Childhood Day’ on November 17th.
Through this, the company plans to spur progress on ‘Synagis (ingredient name: palivizumab)’, which is a preventive drug for respiratory syncytial virus (RSV), which has recently secured the copyright.
AstraZeneca Korea recently participated in the ’10th Early Childhood Hope Campaign’ hosted by the Korean Society of Newborns on the occasion of ‘World Early Childhood Day’ to raise social interest in premature babies and provide correct information on treatment and parenting. Sponsored the delivery activities.
In addition, ahead of the launch of a mobile app that provides information on severe respiratory diseases and prevention, an in-house event was held to name the app. The app provides information on RSV disease and prevention, as well as a function to check whether RSV prevention drugs are paid by entering the date of birth of an early child.
In addition, AstraZeneca Korea is accelerating its activities related to ‘Synagis’, an RSV preventive drug for infants and toddlers, which has secured the copyright as of July.
Synagis is an injection to prevent serious lower respiratory tract disease in children at high risk for RSV disease. Children born under 35 weeks of gestation and under 6 months of age at the beginning of the RSV epidemic season; children under 2 years of age who required treatment for bronchopulmonary dysplasia within the last 6 months; and 2 with hemodynamically significant congenital heart disease It can be administered to children under the age of three.
According to the results of the IMpact-RSV study, Synagis reduced the risk of hospitalization due to RSV by 78% compared to placebo in children born under 35 weeks of gestation and under 6 months of age.
‘Synagis’ can be administered up to 5 times, once a month, from October to March, during the RSV epidemic season. The first dose is available from September before the beginning of the RSV season, and should be administered once a month during the RSV epidemic season until March.
Kim Yong-joon, managing director of AstraZeneca Korea Respiratory Immunity Division, said, “On the occasion of World Early Childhood Day, we are happy to raise awareness about respiratory diseases that can be fatal to infants and to contribute to disease prevention and treatment.” We will continue to make efforts to contribute to the treatment of respiratory diseases in infants and young children in Korea through activities and provision of correct information for parents of premature infants.”
